CN
Our Four Proprietary Antibody Platforms
At CentryMed, we are pioneering next-generation T-Cell Engagers through a world-class antibody discovery and development engine. Our four fully proprietary technology platforms are purpose-built to create highly selective, multifunctional TCEs that address significant unmet medical needs.
时迈药业
时迈药业
Multichannel Antibody Discovery Platform
Integration of ultra-large fully human IgM antibody libraries and multispecies immune repertoires
Achieving 100% discovery rate of high-affinity antibodies
时迈药业
H-BiTE: T-cell Engaging (TCE) Bispecific Antibody Platform
Optimized pharmacology for bispecific antibodies
Enhanced target engagement with improved therapeutic index
时迈药业
Pro-BiTE: Protease-Activated T-cell Engaging Antibody Platform
Next-generation antibody activation for improved safety & efficacy
Controlled activation for tumor-selective therapeutics
时迈药业
Multifunctional T-cell Engager Platform
High-precision immune targeting with multi-functional design
Expanding efficacy for complex disease mechanisms
时迈药业
时迈药业
时迈药业
Multichannel Antibody Discovery Platform
Harnessing ultra-large fully human IgM antibody libraries
4 ultra-large human IgM libraries: Fab and dAb formats with industry-leading diversity and rapid screening cycles (1–2 weeks). dAb capabilities are extremely rare globally.
Advantages:
High epitope diversity and affinity flexibility
Fully human antibodies—no humanization needed
Rapid candidate generation
Animal immune libraries: Proprietary hybridoma + phage display platforms for mouse, rabbit, and monkey. Enable broader epitope coverage and higher-quality antibodies.
时迈药业
H-BiTE: T-cell Engaging (TCE) Bispecific Antibody Platform
Enhanced Potency, Safety, and Manufacturability
Designed to overcome poor druggability and safety challenges of traditional bispecifics
Key features:
Extended therapeutic window with favorable safety profile
Monoclonal-like manufacturability—simple, stable, no aggregation or degradation
Optimized pharmacokinetics and dual-target binding efficiency
时迈药业
Pro-BiTE: Protease-Activated T-cell Engaging Antibody Platform
Next-Generation Safety Switch for Targeted Immune Activation
Global first-in-class design, relying on tumor-specific protease activation
Mechanism:
Inactive in normal tissue and blood
Activated only in tumor microenvironment
Over 10,000-fold sealing efficiency; >100x wider therapeutic window
Demonstrated excellent tolerability in non-human primates, with 100-fold safety improvement
时迈药业
Multifunctional T-cell Engager Platform
Multifunctional Precision for Complex Disease Mechanisms
Flexible structural formats suited to diverse target combinations
Key benefits:
Simultaneous mechanisms of action for greater efficacy
Broad applicability to hard-to-target cancers
Mitigates resistance and relapse from single-target therapies
Tunable design enables balance between potency and safety